Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $39.8752W HIGH $90.75
Volume
4.38 M
Value Traded
52.86 M
Short % Float
11.1%
-3.31%Week
+21.19%1 Month
+25.16%3 Month
+15.6%6 Month
+134.97%5 Year
+127.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.62 B
EPS (TTM)
-7.15
P/E Ratio
-
Ent. Value
9.13 B
Total Shares
148.81 M
Float Shares
145.40 M
Insiders
2.29%
Institutions
111.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PCVX Catalyst Timeline
Dated clinical, regulatory and corporate events for Vaxcyte, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vaxcyte, Inc.
306Total events
11Upcoming
61Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Closing of $1.15B public offerings of common stock, pre-funded warrants and convertible senior notes
▼Equity OfferingCorporate
Pricing of concurrent public offerings of common stock and pre-funded warrants
◆Debt Royalty FinancingCorporate
Pricing of $500 million 1.50% convertible senior notes due 2032
▲Topline ReadoutVAX-31Clinical Data
Positive topline results from OPUS-1 pivotal adult Phase 3 trial of VAX-31
invasive pneumococcal disease (IPD) and pneumococcal pneumoniasource ↗
▲Safety Data UpdateVAX-31Clinical Data
VAX-31 well tolerated with safety profile similar to PCV20 and PCV21 across all ages studied in OPUS-1
invasive pneumococcal disease and pneumococcal pneumoniasource ↗
▲Primary Endpoint MetVAX-31Clinical Data
VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older
invasive pneumococcal disease (IPD) and pneumococcal pneumoniasource ↗
▼Equity OfferingCorporate
Vaxcyte commences $500M public offering of common stock and pre-funded warrants
▲Enrollment CompleteVAX-31Trial
Enrollment completed for OPUS-1 Phase 3 trial
pneumococcal diseasesource ↗
◆Topline ReadoutVAX-31Clinical Data
Topline safety, tolerability and immunogenicity data from primary three-dose immunization series of VAX-31 infant Phase 2 study expected
Infant pneumococcal diseasesource ↗
▲First Patient DosedVAX-A1Trial
First participant dosed in Phase 1 study of VAX-A1
Group A Streptococcussource ↗
▲First Patient DosedVAX-A1Trial
First participant dosed in VAX-A1 Phase 1 study
Group A Streptococcussource ↗
▲Enrollment CompleteVAX-31Trial
Enrollment completed for OPUS-1 Phase 3 trial
Invasive Pneumococcal Disease and Pneumoniasource ↗
●Manufacturing MilestoneCMC / Inspection
Completed construction of dedicated large-scale manufacturing facility with Lonza
◆Oral PresentationPresentation
Vaxcyte management to present at 25th Annual Needham Virtual Healthcare Conference
◆Topline ReadoutVAX-31Clinical Data
Topline safety, tolerability and immunogenicity data from primary immunization series
invasive pneumococcal diseasesource ↗
▲Enrollment CompleteVAX-31Trial
Enrollment completed in OPUS-1 Phase 3 trial of VAX-31
Invasive Pneumococcal Disease and Pneumoniasource ↗
▲PublicationVAX-31Presentation
Positive VAX-31 Phase 1/2 adult data published in The Lancet Infectious Diseases
Invasive Pneumococcal Disease and Pneumoniasource ↗
◆Oral PresentationPresentation
Vaxcyte management to present at Guggenheim Emerging Outlook: Biotech Summit
▲First Patient DosedVAX-31Trial
First participants dosed in OPUS-3 Phase 3 trial evaluating VAX-31 in adults previously vaccinated with lower-valency pneumococcal vaccines
pneumococcal diseasesource ↗
▼Equity OfferingCorporate
Closing of $632.5 million public offering including full exercise of underwriters' option
▼Equity OfferingCorporate
Commencement of proposed public offering of $500M common stock and pre-funded warrants
▲First Patient DosedVAX-31Trial
First participants dosed in Phase 3 trial evaluating VAX-31 with seasonal influenza vaccine
pneumococcal disease (adult)source ↗
▲Enrollment CompleteVAX-31Trial
Enrollment completed in Phase 2 dose-finding study in infants (n=905)
pneumococcal disease (infant)source ↗
◆Trial InitiationVAX-31Trial
Initiation of Phase 3 trial in adults previously vaccinated with pneumococcal vaccines
pneumococcal disease (adult)source ↗
●Manufacturing MilestoneCMC / Inspection
Established North Carolina presence and buildout of custom PCV fill-finish line
▲Enrollment CompleteVAX-31Trial
Enrollment completed for VAX-31 infant Phase 2 dose-finding study
Invasive Pneumococcal Disease (infant)source ↗
▲Enrollment CompleteVAX-31Trial
Enrollment completed in VAX-31 infant Phase 2 dose-finding study
infant pneumococcal diseasesource ↗
●Manufacturing MilestoneCMC / Inspection
Completion of dedicated Lonza manufacturing facility for PCV candidates
◆Topline Readoutdose of VAX-24Clinical Data
Balance of VAX-24 infant Phase 2 dose-finding study data expected
Infant pneumococcal diseasesource ↗
▲First Patient DosedVAX-31Trial
First participants dosed in OPUS Phase 3 noninferiority trial
Invasive Pneumococcal Disease and Pneumoniasource ↗
◆Trial InitiationVAX-31Trial
Initiation of VAX-31 adult pivotal, non-inferiority study
pneumococcal disease (adult)source ↗
◆Full Resultsdose of VAX-24Clinical Data
Full post-dose 4 booster data expected
invasive pneumococcal diseasesource ↗
◆Topline Readoutdose of VAX-24Clinical Data
Topline data from booster dose of VAX-24 infant Phase 2 study
pneumococcal diseasesource ↗
▲Full Resultsdose of VAX-24Clinical Data
Final data from VAX-24 infant Phase 2 dose-finding study
pneumococcal disease (infant)source ↗
◆Trial InitiationVAX-31Trial
Initiation of VAX-31 adult Phase 3 pivotal non-inferiority study
pneumococcal conjugate vaccine (PCV) adultsource ↗
▲Partnership / LicenseCorporate
New agreement with Thermo Fisher Scientific for fill-finish manufacturing
▲Enrollment UpdateVAX-31Trial
VAX-31 infant Phase 2 study advanced to third stage with new Optimized Dose arm
invasive pneumococcal diseasesource ↗
▲Enrollment MilestoneVAX-31Trial
Modified VAX-31 infant Phase 2 study advanced to third and final stage
pneumococcal disease (infant)source ↗
Past FDA Catalysts and PDUFA Decisions
How PCVX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-05 | VAX-31 | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$1.3B
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 30%
Mid Cap(rank 199 of 660)
Percentile Rank
Vaxcyte, Inc. carries a moderate pipeline score (44/100), with $1.6B risk-adjusted pipeline value, led by VAX-31 in Pneumococcal Vaccines (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VAX-31 Monoclonal antibodyNCT06720038 | Pneumococcal Vaccines | Phase 3 | ACTIVE NOT_RECRUITING | 8,106 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every PCVX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VAX-31 Breakthrough | invasive pneumococcal disease and pneumococcal pneumonia | Phase 3 | 2026-10-05 | All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met the prespecified noninferiority criteria (lower bound of the 95% confidence interval (LBCI) >0.667); VAX-31 met all 11 primary noninferiority assessments based on opsonophagocytic activity (OPA) geometric mean ratios (GMRs); All nine met the prespecified OPA GMR noninferiority criterion (LBCI >0.667); All eight met the prespecified OPA GMR noninferiority criterion (LBCI >0.667); The three serotypes unique to VAX-31 and cross-reactive serotype 20B met the OPA GMR superiority criterion (LBCI >2.0)Read More | Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cowan ElviaOfficer (SVP, Finance & CAO) | Option | 19,000 46,860 held | $25.92 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PCVX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 5.8 % (-18.3 %) | 667.02 M | 11.47 M |
PCVX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PCVX ranks across every disease it competes in
Competitive Position is a premium feature
See how PCVX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPCVX News
PCVX▲ +9.4%today
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
Vaxcyte, Inc. has successfully closed its public offerings, raising approximately $1.15 billion. The funds will support the clinical development of its VAX-31 vaccine programs and enhance manufacturing capabilities. This includes ongoing Phase 3 and Phase 2 trials, as well as preparations for a potential U.S. launch of VAX-31 in adults.
Read more →PCVX▲ +9.4%today
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte, Inc. has announced the pricing of concurrent public offerings totaling $1 billion, consisting of common stock, pre-funded warrants, and convertible senior notes. The proceeds will primarily support the clinical development of its VAX-31 vaccine programs and enhance manufacturing capabilities. The offerings are set to close on October 9, 2026, subject to customary conditions.
Read more →PCVX▼ -9.6%on this newsshared move
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte, Inc. has initiated public offerings totaling $1 billion, comprising common stock, pre-funded warrants, and convertible senior notes. The proceeds will primarily fund the clinical development of its VAX-31 vaccine programs and other corporate purposes. The offerings are not contingent on each other, but market conditions may impact their completion.
Read more →PCVX▲ +30.7%on this newsshared move
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte announced positive topline results from the OPUS-1 Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine. The vaccine met all primary immunogenicity endpoints across various age groups and demonstrated a safety profile comparable to existing vaccines. These results will support a planned Biologics License Application submission in 2028.
Read more →PCVX▲ +30.7%on this newsshared move
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte, Inc. announced a webcast and conference call to present topline data from the OPUS-1 Phase 3 trial of its 31-valent pneumococcal conjugate vaccine, VAX-31. The trial evaluates the vaccine's safety, tolerability, and immunogenicity. The event is scheduled for October 5, 2026, and will also be archived on the company's website.
Read more →PCVXVaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte has appointed Luis Jodar, Ph.D., as Chief Medical Officer and David McAvoy, J.D., as Chief Legal Officer. The company also updated its timeline for topline data from the VAX-31 Phase 3 OPUS-1 trial, now expected by the end of October 2026. These changes aim to bolster leadership and support the potential commercialization of VAX-31.
Read more →PCVXVaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. announced its participation in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings, with webcasts available for public access. The company is focused on innovative vaccine development, including its lead candidates VAX-31 and VAX-24.
Read more →PCVX▲ +5.3%on this news
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Vaxcyte reported its financial results for Q2 2026, highlighting a robust cash position of $2.5 billion. The company anticipates key data readouts from its VAX-31 Phase 3 trials in the coming months, which are crucial for a potential BLA submission. Additionally, Vaxcyte has initiated a Phase 1 study for VAX-A1, targeting Group A Streptococcus.
Read more →PCVXVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte has initiated a Phase 1 study for VAX-A1, a vaccine aimed at preventing diseases caused by Group A Streptococcus in healthy adults. The study will assess safety and tolerability, with initial data expected in late 2027. Group A Strep poses a significant public health threat, with no existing vaccine and rising infection rates.
Read more →PCVX▼ -9.8%on this news
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte, Inc. reported its first quarter 2026 financial results, highlighting the completion of enrollment in its OPUS Phase 3 trials for VAX-31, aimed at preventing invasive pneumococcal disease. The company anticipates topline data from OPUS-1 in Q4 2026 and results from OPUS-2 and OPUS-3 in H1 2027. Vaxcyte also plans to initiate a Phase 1 study for its VAX-A1 vaccine candidate in mid-2026, supported by a strong financial position.
Read more →PCVXVaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 14, 2026. The company's management will engage in a fireside chat, which will be accessible via a live webcast. Vaxcyte is known for its innovative vaccine development, including its leading candidates VAX-31 and VAX-24.
Read more →PCVXVaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte has completed enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a next-generation pneumococcal conjugate vaccine. The OPUS-1 trial will compare VAX-31's safety and immunogenicity against existing vaccines, while OPUS-2 will assess its administration alongside seasonal influenza vaccines. Results are anticipated in late 2026 and early 2027, respectively.
Read more →PCVXPositive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte announced positive results from the Phase 1/2 study of its VAX-31 vaccine, demonstrating strong immune responses and safety comparable to Prevnar 20. The findings support the advancement of VAX-31 into a comprehensive Phase 3 program, aiming to enhance protection against invasive pneumococcal disease and pneumonia in adults aged 50 and older. The vaccine is designed to cover a broad spectrum of serotypes, potentially improving disease prevention significantly.
Read more →PCVXVaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte, Inc. reported its fourth quarter and full year 2025 financial results, highlighting progress in its VAX-31 Phase 3 clinical program for pneumococcal vaccines. The company has completed enrollment for its infant Phase 2 study and is advancing its early-stage pipeline with plans for a Phase 1 study of VAX-A1. Vaxcyte also announced strong financials, with $2.4 billion in cash and investments.
Read more →PCVXVaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Vaxcyte has initiated the OPUS-3 Phase 3 trial for its VAX-31 vaccine, targeting adults previously vaccinated with lower-valency pneumococcal vaccines. This trial aims to assess the safety, tolerability, and immunogenicity of VAX-31, which is designed to cover a wide range of pneumococcal diseases. The company expects to report topline data from this and other related trials by 2027.
Read more →PCVXVaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc. will report its fourth quarter and full year 2025 financial results on February 24, 2026. Following the report, the company will host a conference call and webcast to discuss the results and provide a business update. Vaxcyte is known for its innovative vaccine candidates, including VAX-31 and VAX-24, aimed at preventing invasive pneumococcal disease.
Read more →PCVXVaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte, Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026. The management will engage in a fireside chat, which will be available via live webcast. Vaxcyte is known for its innovative vaccine candidates, including VAX-31 and VAX-24, aimed at preventing invasive pneumococcal disease.
Read more →PCVXVaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte, Inc. has successfully closed a public offering of 12,650,000 shares at $50.00 each, raising a total of $632.5 million. This includes the full exercise of an option by underwriters to purchase additional shares. The funds will support Vaxcyte's ongoing development of its vaccine candidates, including VAX-31 and VAX-24, aimed at preventing invasive pneumococcal disease.
Read more →About Vaxcyte, Inc.
Headquarters825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
BIOPHARMAWATCH ELITE PLUS
Trade the next PCVX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime